|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1975-7-7
|
|
pubmed:abstractText |
Extensive DNA damage was found in tumor cells after therapeutic doses of daunorubicin and adriamycin (2.5 - 10 mg/kg) were administered to mice bearing lymphocytic leukemia (P-288). After low doses (0.6 mg/kg), DNA breaks were evident as early as 1-3 hr after daunorubicin and as determined with adriamycin the damage lasted as long as 72 hr. In a comparison, actinomycin D produced smaller amounts of damage by 3 hr after the administration of maximally tolerated doses (0.8 mg/kg) and even less after 0.4 mg/kg. These experiments indicate that the antitumor activity of daunorubicin and adriamycin in treated mice may result from damage to the cellular DNA.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0034-5164
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
51-64
|
|
pubmed:dateRevised |
2009-10-27
|
|
pubmed:meshHeading |
pubmed-meshheading:1124321-Animals,
pubmed-meshheading:1124321-Carbon Radioisotopes,
pubmed-meshheading:1124321-Cells, Cultured,
pubmed-meshheading:1124321-Centrifugation, Density Gradient,
pubmed-meshheading:1124321-DNA, Neoplasm,
pubmed-meshheading:1124321-Dactinomycin,
pubmed-meshheading:1124321-Daunorubicin,
pubmed-meshheading:1124321-Doxorubicin,
pubmed-meshheading:1124321-Female,
pubmed-meshheading:1124321-Leukemia, Lymphoid,
pubmed-meshheading:1124321-Mice,
pubmed-meshheading:1124321-Mice, Inbred Strains,
pubmed-meshheading:1124321-Neoplasm Transplantation,
pubmed-meshheading:1124321-Nucleic Acid Denaturation,
pubmed-meshheading:1124321-Sucrose,
pubmed-meshheading:1124321-Time Factors,
pubmed-meshheading:1124321-Transplantation, Homologous,
pubmed-meshheading:1124321-Tritium
|
|
pubmed:year |
1975
|
|
pubmed:articleTitle |
DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
